MENU
+Compare
OCUL
Stock ticker: NASDAQ
AS OF
Feb 21 closing price
Price
$7.00
Change
-$0.25 (-3.45%)
Capitalization
1.1B

OCUL Ocular Therapeutix Forecast, Technical & Fundamental Analysis

a developer of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology

Industry Biotechnology
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for OCUL with price predictions
Feb 21, 2025

OCUL in upward trend: price expected to rise as it breaks its lower Bollinger Band on February 10, 2025

OCUL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 38 cases where OCUL's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for OCUL's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where OCUL advanced for three days, in of 256 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on February 06, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on OCUL as a result. In of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for OCUL turned negative on February 10, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

The 50-day moving average for OCUL moved below the 200-day moving average on February 21, 2025. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where OCUL declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for OCUL entered a downward trend on February 21, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.122) is normal, around the industry mean (12.496). P/E Ratio (0.000) is within average values for comparable stocks, (84.451). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.603). OCUL has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (15.798) is also within normal values, averaging (251.218).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. OCUL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. OCUL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
OCUL
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

OCUL is expected to report earnings to rise 14.05% to -25 cents per share on March 06

Ocular Therapeutix OCUL Stock Earnings Reports
Q4'24
Est.
$-0.25
Q3'24
Beat
by $0.02
Q2'24
Missed
by $0.04
Q1'24
Missed
by $0.31
Q4'23
Missed
by $0.05
The last earnings report on November 14 showed earnings per share of -21 cents, beating the estimate of -23 cents. With 661.68K shares outstanding, the current market capitalization sits at 1.10B.
A.I. Advisor
published General Information

General Information

a developer of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Other
Address
15 Crosby Drive
Phone
+1 781 357-4000
Employees
267
Web
https://www.ocutx.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
FFNAX13.30N/A
N/A
Fidelity Advisor Asset Manager 40% A
EAEAX37.37N/A
N/A
Eaton Vance Tax-Managed Eq Aset Allc A
SUVCX10.62N/A
N/A
PGIM Quant Solutions Large-Cap Val C
FSOSX14.63N/A
N/A
Fidelity Series Overseas
AGLYX13.37-0.07
-0.52%
Ariel Global Institutional

OCUL and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, OCUL has been loosely correlated with RCUS. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if OCUL jumps, then RCUS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OCUL
1D Price
Change %
OCUL100%
-3.45%
RCUS - OCUL
46%
Loosely correlated
+3.07%
EYPT - OCUL
45%
Loosely correlated
-3.15%
XENE - OCUL
39%
Loosely correlated
+0.89%
CCCC - OCUL
39%
Loosely correlated
+0.67%
YMAB - OCUL
38%
Loosely correlated
-5.30%
More